Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (9): 69-78.doi: 10.6040/j.issn.1671-7554.0.2023.0150

• Clinical Medicine • Previous Articles     Next Articles

Screening of prognosis-related RNA editing sites in clear cell renal cell carcinoma

SONG Zhaolu1, DONG Zhengxuan2, PENG Chuanzhen1, HUANG Caina2, HU Keqing1, HUANG Yongsheng3, YAN Lei3   

  1. 1. Department of Urology, Jiaozhou Central Hospital, Qingdao 266300, Shandong, China;
    2. Department of Emergency, Qingdao Municipal Hospital, Qingdao 266000, Shandong, China;
    3. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2023-02-17 Published:2023-10-10

PDF (PC)

79

Abstract: Objective To explore RNA editing sites associated with survival and prognosis in clear cell renal cell carcinoma(ccRCC). Methods After the expression data of RNA editing sites in the Cancer Genome Atlas(TCGA)were downloaded, the minimum absolute contraction, selection operator(LASSO)and Cox regression were used to identify RNA editing sites closely associated with ccRCC prognosis. A prognostic model and nomogram were constructed after the risk scores were calculated based on the multivariate Cox results. The accuracy of the prognostic model and nomogram was evaluated with the receiver operating characteristic(ROC)curve, and the relevant functional analysis was performed. Results A total of 25 RNA editing sites associated with ccRCC prognosis were screened. Patients were divided into the high-risk group(n=222)and low-risk group(n=226)based on the median risk score. Kaplan-Meier survival analysis showed that the overall survival(OS)and progression-free survival(PFS)were in shorter in the high-risk group than in the low-risk group(P<0.001). The area under the ROC curve(AUC)of 1-year, 3-year and 5-year survival predicted by the prognosis model were 0.801, 0.824 and 0.806, and those predicted by the nomogram were 0.858, 0.833 and 0.821, respectively. There were differences in biological function and drug sensitivity between the two groups. Conclusion The 25 RNA editing sites are expected to become new prognostic markers and drug therapeutic targets for patients with ccRCC.

Key words: Renal clear cell carcinoma, RNA editing, Prognostic model, Immunotherapy

CLC Number: 

  • R692
[1] Linehan WM, Schmidt LS, Crooks DR, et al. The metabolic basis of kidney Cancer [J]. Cancer Discov, 2019, 9(8): 1006-1021.
[2] 中国医疗保健国际交流促进会泌尿健康促进分会. 肾癌基因检测中国专家共识(2021版)[J]. 现代泌尿外科杂志, 2022, 27(3): 192-200. China Association for the Promotion of International Exchange of Medical Care Urinary Health Promotion Branch. Chinese expert consensus on kidney cancer gene testing(2021 version)[J]. Journal of Modern Urology, 2022, 27(3): 192-200.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1): 7-30.
[4] Go H, Kang MJ, Kim PJ, et al. Development of response classifier for vascular endothelial growth factor receptor(VEGFR)-tyrosine kinase inhibitor(TKI)in metastatic renal cell carcinoma [J]. Pathol Oncol Res, 2019, 25(1): 51-58.
[5] Liu J, Wang F, Zhang Y, et al. ADAR1-Mediated RNA editing and its role in cancer [J]. Front Cell Dev Biol, 2022, 10: 956649. doi: 10.3389/fcell.2022.956649.
[6] Kurkowiak M, Arcimowicz L, Chrusciel E, et al. The effects of RNA editing in cancer tissue at different stages in carcinogenesis [J]. RNA Biol, 2021, 18(11): 1524-1539.
[7] Park E, Jiang Y, Hao L, et al. Genetic variation and microRNA targeting of A-to-I RNA editing fine tune human tissue transcriptomes [J]. Genome Biol, 2021, 22(1): 77. doi: 10.1186/s13059-021-02287-1.
[8] Peng X, Xu X, Wang Y, et al. A-to-I RNA editing contributes to proteomic diversity in cancer [J]. Cancer Cell, 2018, 33(5): 817-828.
[9] Chigaev M, Yu H, Samuels DC, et al. Genomic positional dissection of RNA editomes in tumor and normal samples [J]. Front Genet, 2019, 10: 211. doi: 10.3389/fgene.2019.00211. eCollection 2019.
[10] Sun Z, Qin X, Fang J, et al. Multi-omics analysis of the expression and prognosis for FKBP gene family in renal cancer [J]. Front Oncol, 2021, 11: 697534. doi: 10.3389/fonc.2021.697534. eCollection 2021.
[11] Teng PC, Liang Y, Yarmishyn AA, et al. RNA Modifications and epigenetics in modulation of lung cancer and pulmonary diseases [J]. Int J Mol Sci, 2021, 22(19):10592. doi: 10.3390/ijms221910592.
[12] Song B, Shiromoto Y, Minakuchi M, et al. The role of RNA editing enzyme ADAR1 in human disease [J]. Wiley Interdiscip Rev RNA, 2022, 13(1): e1665. doi: 10.1002/wrna.1665.
[13] Jiang L, Hao Y, Shao C, et al. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance [J]. Clin Invest, 2022, 132(6): e143397. doi: 10.1172/JCI143397.
[14] Nakamura K, Shigeyasu K, Okamoto K, et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer [J]. Gynecologic Oncology, 2022, 166(2): 326-333.
[15] Shen P, Yang T, Chen Q, et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing [J]. Mol Cancer, 2021, 20(1): 51. doi: 10.1186/s12943-021-01333-7.
[16] Martinez HD, Jasavala RJ, Hinkson I, et al. RNA editing of androgen receptor gene transcripts in prostate cancer cells [J]. J Biol Chem, 2008, 283(44): 29938-29949.
[17] Shigeyasu K, Okugawa Y, Toden S, et al. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer [J]. JCI Insight, 2018, 3(12): e99976. doi: 10.1172/jci.insight.99976.
[18] Okugawa Y, Toiyama Y, Shigeyasu K, et al. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer [J]. Transl Med, 2018, 16(1): 366. doi: 10.1186/s12967-018-1740-z.
[19] Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy [J]. Cell, 2017, 168(4): 707-723.
[20] 胡立勇,钟浩,房娟娟,等. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报(医学版), 2023, 61(4): 49-55. HU Liyong, ZHONG Hao, FANG Juanjuan, et al. Prognostic value of CCR gene in clear cell renal cell carcinoma based on database [J]. Journal of Shandong University(Health Sciences), 2023, 61(4): 49-55.
[21] Tang SJ, Shen H, An O, et al. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development [J]. Nat Commun, 2020, 11(1): 799.
[22] 杨朝华, 田宇, 安治国. RNA编辑与肿瘤[J]. 中国实验诊断学, 2004, 8(1): 89-91. YANG Zhaohua, TIAN Yu, AN Zhiguo. RNA editing and tumor [J]. Chinese Journal of Laboratory Diagnosis, 2004, 8(1): 89-91.
[23] Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation [J]. Genes Dev, 2015, 29(13): 1343-1355.
[24] Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma [J]. Nat Med, 2013, 19(2): 209-216.
[25] Xu LD, Öhman M. ADAR1 Editing and its role in cancer [J]. Genes(Basel), 2018, 10(1):12. doi: 10.3390/genes10010012.
[26] Wu YM, Guo Y, Yu H, et al. RNA editing affects cis-regulatory elements and predicts adverse cancer survival [J]. Cancer Med, 2021, 10(17): 6114-6127.
[1] HU Liyong, ZHONG Hao, FANG Juanjuan, GUO Wei, ZHANG Yulu, FAN Yidong. Prognostic value of CCR gene in clear cell renal cell carcinoma based on database [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 49-55.
[2] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[3] Huijiang GAO,Yucheng WEI. Minimally invasive sleeve lobectomy: opportunities and challenges in the era of immunotherapy [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 23-27.
[4] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[5] DENG Xiaohui, GUO Ling. Applications and progress of immunotherapy in repeated implantation failure [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 32-37.
[6] PANG Zhaofei, LIU Yong, ZHAO Xiaogang, YAN Tao, CHEN Xiaowei, DU Jiajun. Construction of a stemness-based scoring model predicting the efficacy of immunotherapy in lung adenocarcinoma based on public databases [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 19-28.
[7] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[8] WANG Zhao. Advances in the clinical treatment of hemophagocytic lymphohistiocytosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 44-49.
[9] WU Depei, CHEN Xiaochen. Current situation and prospect of immunotherapy for lymphoma [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 13-20.
[10] HUANG Xiaojun. Advances of cellular immunotherapy for hematologic malignancies [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 1-5.
[11] ZHENG Min, ZHANG Lan. Current situation and development trend of CAR-T in anti-tumor research [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 1-6.
[12] ZHANG Lin1, HOU Yan-hong1, ZHANG Jian2, HU Jing1, ZHANG Jing1. Experimental study of anti-CD3/anti-EGFR bispecific antibody therapeutic activity against pancreatic cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 15-19.
[13] JIANG Yu-xin, MA Yu-cheng, LI Chao-pin. Effect of immunotherapy on asthma mice with chimeric allergens derived
from the major allergen group 2 genes of dust mites [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 50-.
[14] LI Xue-jiao. The efficacy of specific immunotherapy combined with  Yupingfeng granules for atopic dermatitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(7): 144-146.
[15] Lv Yi-jing, REN Min, WANG Bo, GE Ru-qing, ZHANG Ji-dong. Expressions of CTGF and EZH2 in renal clear cell carcinoma  and their clinical significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(3): 85-89.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[2] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[3] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[4] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[5] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[6] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[7] XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67 -71 .
[8] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60 -66 .
[9] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
[10] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd